Drug Trial Radar · NCT06575647
Vivax Elimination With Tafenoquine (VET) Study
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,242
Actual
Start
Feb 19, 2025
Primary completion
Oct 4, 2025
Study completion Oct 4, 2025
Sponsor
- Lead sponsor
- Shoklo Malaria Research UnitAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Mahidol Oxford Tropical Medicine Research Unit
- First posted
- Aug 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Theoretically, so long as there is a sink-source for malaria, transmission could be sustained at very low level (even at sub-microscopic oscillation) and reintroduce malaria either as sporadic cases or as resurgent outbreak. Uncertainty or shortage in financing has typically limited the malaria control or elimination projects to go further beyond the "Pre-elimination phase". Since malaria is no longer a top scoring mortality in national statistics in South East Asia, the governments/stakeholders are less willing to allocate from the austerity budget. There are proven evidence of resurgences after cessation of intervention programs where over 90% of all resurgence events were attributed to the interruption of malaria control programmes. In Karen state Myanmar-Thailand border, multiple factors including a cascade of political, financial, and logistical fiascos have compounded on the ongoing malaria elimination activities. Deleterious impacts after military coup since 2021 February including cessation of foreign investment, humanitarian aids, Civil Dis-obedience Movement of government staff and resuming armed-conflicts have strained the nearly failed health infrastructure of the country to a collapse stage. Interruption of the National Malaria Control activities due to the health system failure and accelerating combats countrywide could inevitably lead to the overturn in recently achieved malaria pre-elimination status especially in Karen state. The disruption in health services within Myanmar is already resulting in an increase in malaria. Supply of the first line antimalarial drug artemether-lumefantrine, and other essential malaria control interventions, has been interrupted. The study is proposed to evaluate the impact of Mass Drug Administration (MDA) in 3 villages in Karen state with consistently high incidence of P. vivax and spatially clustered within 5 km radius. This proposal outlines a study to assess the feasibility and the safety of tafenoquine MDA.
Conditions
- Malaria
- Malaria, Vivax
- Plasmodium Vivax
- Plasmodium Vivax Malaria
Interventions
TafenoquineDrug
Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia). Tafenoquine will be given as follows, \>10 kg to ≤ 20 kg - 150 mg (1 tab), \>20 kg to ≤ 35 kg - 300 mg (2 tabs), \> 35 kg - 450 mg (3 tabs)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Serious Adverse Events (SAEs) to assess safety and tolerability of Tafenoquine MDATime frame: Baseline survey to end of Month-1 survey
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shoklo Malaria Research Unit (SMRU)
Mae Sot, Changwat Tak, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.